Patient-derived organoids enhance treatment outcomes for pancreatic cancer.

A novel approach to matching patients with pancreatic ductal adenocarcinoma (PDAC) to effective chemotherapy has shown significant promise. Patient-derived organoids (PDOs) matched 91% of patients to standard treatments, improving CA 19-9 markers and lymph node staging. Notably, those who received therapies well-aligned with their PDO chemosensitivity experienced better recurrence-free and overall survival compared to misaligned treatments. These findings suggest that PDO pharmacotyping may optimize therapeutic strategies and improve patient quality of life.